Sign in
4

Changes in Ownership

Rapport Therapeutics, Inc. Filed Acc 0001193125-26-359189

Chief Development Officer sold 404 shares at $49.90 ($20,160)

  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Yeleswaram Krishnaswamy Chief Development Officer 2026-08-19 Sale 10b5-1 −404 $49.90 $20,160 246,022 D
Open-market sales · 404 sh · avg $49.90 · $20,160
Loading xslF345X06/ownership.xml…